ConvaTec logo

CTEC - ConvaTec News Story

203.2p -1.1  -0.5%

Last Trade - 15/10/21

Sector
Healthcare
Size
Large Cap
Market Cap £4.09bn
Enterprise Value £4.84bn
Revenue £1.45bn
Position in Universe 219th / 1785

ConvaTec Group PLC - Scrip Dividend - Calculation Price

Thu 9th September, 2021 3:00pm
RNS Number : 3137L
ConvaTec Group PLC
09 September 2021
 

Scrip Dividend - calculation price

 

 

Reading, United Kingdom (9 September 2021)

On 30 July 2021, the Board of Directors of ConvaTec Group Plc ("ConvaTec" or "the Company") declared an interim dividend of 1.717 cents per share ("Interim Dividend"). This Interim Dividend is to be paid on 14 October 2021 to shareholders on the share register as of 3 September 2021 ("Record Date"). The Interim Dividend is payable in cash, in sterling to holders of ordinary shares. The chosen exchange rate for this payment is $1.397/£1.00, determined on 29 July 2021, giving a total sterling dividend of £24,749,881. A scrip dividend will be made available for this Interim Dividend, allowing shareholders to elect to receive their dividend in the form of new ordinary shares.

The "Calculation Price" for the issue of new ordinary shares under the scrip dividend scheme is:

226.08 pence for each new ordinary share.

This is equivalent to 1 new share for approximately 183.95 shares held prior to the ex-dividend date of 2 September 2021.

The Calculation Price is the average of the middle market quotations of a ConvaTec share, derived from the London Stock Exchange Daily Official List, for the five consecutive business days from 2 September to 8 September 2021 (inclusive).

The latest date for receipt of elections to participate in the scrip dividend scheme for the Interim Dividend is 21 September 2021. Shareholders must return their mandate form by 5pm (BST) or otherwise input their CREST elections to be received by the Company's registrar, Computershare, by 3pm (BST) on 21 September 2021. Elections received after this deadline will apply to subsequent dividends only. Unless revoked by you, your scrip dividend election will apply for all future dividends for which a scrip dividend is offered. Evergreen elections for CREST shareholders cannot be accepted and elections will revert to cash by default after the payment of each dividend.

Details of the scrip dividend scheme are available at www.convatecgroup.com/investors.

TIMETABLE

Key dates in respect of the scrip dividend scheme for the Interim Dividend are:

Ex-dividend Date

   2 September 2021

Record Date

   3 September 2021

Scrip calculation price determined

      2-8 September 2021 (inclusive)

Scrip calculation price available and announced

                           9 September 2021

Mandate delivery deadline for Shares held in uncertificated form

 3.00 p.m. on 21 September 2021

Mandate delivery deadline for Shares held in certificated form

5.00 p.m. on 21 September 2021

  Announcement of the total amount of new shares to be issued

                        28 September 2021

  Dividend payment date

                             14 October 2021

  Dispatch of statement in accordance with section 7 of Scheme

                              14 October 2021

Rules and share certificates, CREST accounts credited/updated,

and first day of dealings in New Shares

                                                                                                           

 

 

Enquiries

Analysts and Investors

Kate Postans, VP Investor Relations

& Corporate Communications                                                    +44 (0)782 644 7807

ir@convatec.com

 

Media

Buchanan: Charles Ryland / Chris Lane                                    +44 (0)207 466 5000                                                                                                 

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

 

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com.

 

 

# # #

END

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVDKCBDNBKDOCK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.